ASTRAZENECA PHARMA 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis
Fri, 29 Mar

ASTRAZENECA PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

ASTRAZENECA PHARMA Income Statement Analysis

  • Operating income during the year rose 5.0% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 25.3% YoY during the fiscal. Operating profit margins witnessed a fall and down at 8.1% in FY18 as against 6.8% in FY17.
  • Depreciation charges decreased by 6.9% increased by 0.0% YoY, respectively.
  • Other income declined by 14.9% YoY.
  • Net profit for the year grew by 29.2% YoY.
  • Net profit margins during the year grew from 3.6% in FY17 to 4.4% in FY18.

ASTRAZENECA PHARMA Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m5,4375,7105.0%
Other incomeRs m144123-14.9%
Total RevenuesRs m5,5815,8334.5%
Gross profitRs m36946325.3%
DepreciationRs m158147-6.9%
InterestRs m000.0%
Profit before taxRs m35543823.4%
TaxRs m15517915.8%
Profit after taxRs m20125929.2%
Gross profit margin%6.88.1
Effective tax rate%43.540.8
Net profit margin%3.64.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ASTRAZENECA PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 2 billion as compared to Rs 2 billion in FY17, thereby witnessing an increase of 8.7%.
  • Current assets rose 28% and stood at Rs 3 billion, while fixed assets fell 14% and stood at Rs 790 million in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 5 billion as against Rs 4 billion during FY17, thereby witnessing a growth of 11%.

ASTRAZENECA PHARMA Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m2,2292,46910.8
 
Current LiabilitiesRs m1,9032,0708.7
Long-term DebtRs m000.0
Total LiabilitiesRs m4,1554,60510.8
 
Current assetsRs m2,5163,20927.6
Fixed AssetsRs m 917790-13.8
Total AssetsRs m4,1554,60510.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ASTRAZENECA PHARMA Cash Flow Statement Analysis

  • ASTRAZENECA PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 88 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -94 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 0 million, an improvement of 0% on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -6 million from the Rs 384 million net cash flows seen during FY17.

ASTRAZENECA PHARMA Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m38188-76.9%
Cash Flow from Investing ActivitiesRs m3-94-
Cash Flow from Financing ActivitiesRs m000.0%
Net Cash FlowRs m384-6-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for ASTRAZENECA PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 10.4, an improvement from the EPS of Rs 8.0 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 1,987.8, stands at 103.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 10.9 times, while the price to sales ratio stands at 4.7 times.
  • The company's price to cash flow (P/CF) ratio stood at 122.3 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs217.5228.4
TTM Earnings per shareRs8.010.4
Diluted earnings per shareRs8.010.4
Price to Cash Flow x138.5122.3
TTM P/E ratiox103.9103.9
Price / Book Value ratiox11.910.9
Market CapRs m49,69549,695
Dividends per share (Unadj.)Rs0.00.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for ASTRAZENECA PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.6x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 10.5% during FY18, from 9.0% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 17.7% during FY18, from 15.9% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 5.6% during FY18, from 4.8% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox1.31.6
Debtors’ DaysDays2935
Interest coveragex0.00.0
Debt to equity ratiox0.00.0
Return on assets%4.85.6
Return on equity%9.010.5
Return on capital employed%15.917.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how ASTRAZENECA PHARMA has performed over the last 5 years, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 926.5 to Rs 1,987.8, registering a gain of Rs 1,061.3 or around 114.5%.

(To know more, check out historical annual results for ASTRAZENECA PHARMA and quarterly results for ASTRAZENECA PHARMA)

Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

TORRENT PHARMA Surges by 7%; BSE HEALTHCARE Index Up 4.5% (Market Updates)

Apr 7, 2020 | Updated on Apr 7, 2020

TORRENT PHARMA share price has surged by 7% and its current market price is Rs 2,214. The BSE HEALTHCARE is up by 4.5%. The top gainers in the BSE HEALTHCARE Index are TORRENT PHARMA (up 6.6%) and ASTRAZENECA PHARMA (up 6.1%). The top losers are ALKEM LABORATORIES (down 0.2%) and BLISS GVS PHARMA (down 0.7%).

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS